Oppenheimer Upgrades Aldeyra Therapeutics to Outperform, Announces $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois upgrades Aldeyra Therapeutics (ALDX) from Perform to Outperform with a $10 price target.

April 03, 2024 | 1:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aldeyra Therapeutics was upgraded by Oppenheimer from Perform to Outperform with a new price target of $10.
Analyst upgrades typically lead to positive short-term price movements as they reflect a positive change in the analyst's view of the company's future prospects. The upgrade from Perform to Outperform suggests that Oppenheimer sees significant upside potential for ALDX, potentially making it more attractive to investors. The announcement of a $10 price target further underscores the analyst's bullish outlook, likely leading to increased investor interest and potentially higher stock prices in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100